Swiss Lions rankings | 2026 edition
Santhera
Santhera is No. 15 in the Pharma & Biotech ranking, with a score of 12.3 out of 100. It is not among the Swiss Lions 100 for 2026. Headquarters: Pratteln, canton of Basel-Landschaft.
- Swiss Lions score
- 12.3
- Swiss Lions 100
- Not in the 100 for 2026
- Pharma & Biotech
- 15of 15
About
Pratteln-based specialty pharmaceutical company, listed on SIX Swiss Exchange, that develops and markets treatments for rare neuromuscular diseases, led by AGAMREE for Duchenne muscular dystrophy.
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on rare neuromuscular diseases. Its lead product is AGAMREE (vamorolone), licensed from ReveraGen and approved for Duchenne muscular dystrophy in the United States, the European Union, the United Kingdom, Switzerland, China, Hong Kong and Canada. Santhera sells AGAMREE directly in Germany, Austria and the UK, and through partners elsewhere: Catalyst Pharmaceuticals in North America, Sperogenix in China, Nxera Pharma in Japan, South Korea and Australasia, and distributors in Central and Eastern Europe, the Gulf states and other regions. The company sold its RAXONE (idebenone) business to Chiesi in 2023. Total revenue was CHF 77.2 million in 2025, and it had 99 employees at year-end.
- AGAMREE (vamorolone) for Duchenne muscular dystrophy
- Out-licensing and partner supply of AGAMREE
Links
How the score is made
Global scale
CHF 77m revenue.
Swiss value
Limited Swiss production.
Global visibility
Online attention across languages, and worldwide search interest.
Impact
No current SBTi target. Not a certified B Corp.
Philanthropy
No charitable foundation found.
Impact and philanthropy together make up the impact measure. How the ranking works.
Key figures
- Revenue used in the ranking
- CHF 77m2025, company
Shares and listing
- Stock exchange
- SIX Swiss ExchangeTicker SANN
- ISIN
- CH1276028821
- Market value
- CHF 212 millionAt the close on 23 October 2026. Source: stockanalysis.com.
- Free float
- 87.1%Shares not held by large long-term shareholders. Source: in.marketscreener.com.
Profit, dividends and employee numbers are published in the company's annual report.
We have not found a published figure for employees in Switzerland for 2025 or 2026, and dividends paid to Swiss shareholders are not published, so neither is shown.
Profile
- Headquarters
- PrattelnCanton of Basel-Landschaft
- Language region
- German-speaking
- Category
- Pharma & Biotech
- Ownership
- Listed, no controlling shareholder
- Chief executive
- Orlando OliveiraSince 2026. Source
- Chair
- Thomas MeierSource
- Founded
- 2004
In Switzerland
- Pratteln BLHeadquarters
Over time
| Year | Revenue | Employees worldwide |
|---|---|---|
| 2025 | CHF 77m | 99 |
| 2024 | CHF 39m | - |
| 2023 | CHF 103m | - |
| 2022 | CHF 8m | - |
As reported by the company, in its reporting currency. Group figures where the brand is part of a group only if stated.
Milestones
- 2023Licenses AGAMREE in North America to Catalyst Pharmaceuticals; sells RAXONE business to Chiesi.
- 2023AGAMREE approved by the US FDA in October and EMA in December.
- 2024AGAMREE launched in Germany, its first market worldwide, in January.
- 2026Orlando Oliveira succeeds Dario Eklund as chief executive on 15 July.
Also in Pharma & Biotech
1RocheScore 77.2
2NovartisScore 75.5
3LonzaScore 56.3
4SandozScore 52.1
5FerringScore 49.8
6SiegfriedScore 44.1
See all 15 brands in Pharma & Biotech.
Sources
- Revenue used in the ranking: santelog.com (2025).
- Company profile, sites, history and milestones: santhera.com, biospace.com.
- Climate target: Science Based Targets initiative dashboard, October 2026. Foundations: Swiss commercial register. B Corp: B Lab directory.
Something out of date?
If a figure is wrong, or Santhera can publish figures for the next edition, tell us. Corrections are recorded with their source.